AP301

DRUG4 trials

Sponsors

Apeptico Forschung und Entwicklung GmbH, Alebund Pty Ltd, Alebund Pharmaceuticals

Conditions

Acute Lung InjuryChronic Kidney Disease(CKD)Chronic Kidney Disease, Receiving DialysisDialysisESRD (End Stage Renal Disease)ESRD (End-Stage Renal Disease)Healthy SubjectsHyperphosphatemia

Phase 1

A Pharmacodynamic Effect Study of AP301 in Healthy Volunteers

CompletedNCT06100627

Alebund Pty LtdHealthy Subjects

Start: 2024-01-11End: 2024-02-28Updated: 2024-05-10

Phase 2

Study in Intensive Care Patients to Investigate the Clinical Effect of Repetitive Orally Inhaled Doses of AP301 on Alveolar Liquid Clearance in Acute Lung Injury

CompletedNCT01627613

Apeptico Forschung und Entwicklung GmbHAcute Lung Injury

Start: 2012-07-31End: 2014-08-31Updated: 2019-11-18

Phase 3

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

RecruitingNCT06933472

Alebund PharmaceuticalsChronic Kidney Disease, Receiving Dialysis, Dialysis, ESRD (End-Stage Renal Disease) +1

Start: 2025-06-13End: 2027-01-10Target: 264Updated: 2026-01-29

AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia

CompletedNCT07030595

Alebund PharmaceuticalsChronic Kidney Disease(CKD), Chronic Kidney Disease, Receiving Dialysis, Dialysis +3

Start: 2023-06-12End: 2025-05-30Updated: 2025-11-17

Related Papers

Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial.

2017-07-2742 citations